On Monday, Cardiff Oncology Inc (NASDAQ: CRDF) was -6.94% drop from the session before settling in for the closing price of $3.17. A 52-week range for CRDF has been $1.90 – $4.99.
During the last 5-year period, the sales growth of Healthcare Sector giant was 19.36%. When this article was written, the company’s average yearly earnings per share was at 19.09%. With a float of $61.36 million, this company’s outstanding shares have now reached $67.09 million.
Cardiff Oncology Inc (CRDF) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cardiff Oncology Inc stocks. The insider ownership of Cardiff Oncology Inc is 8.91%, while institutional ownership is 31.16%. The most recent insider transaction that took place on Jul 30 ’25, was worth 673,750. In this transaction Director of this company bought 275,000 shares at a rate of $2.45, taking the stock ownership to the 1,330,676 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 15,000 for $2.45, making the entire transaction worth $36,750. This insider now owns 1,345,676 shares in total.
Cardiff Oncology Inc (CRDF) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.21 earnings per share (EPS) during the time that was better than consensus figure (set at -0.25) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.03% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
You can see what Cardiff Oncology Inc (CRDF) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 397.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Looking closely at Cardiff Oncology Inc (NASDAQ: CRDF), its last 5-days average volume was 1.37 million, which is a jump from its year-to-date volume of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 80.45%.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 74.47%, which indicates a significant increase from 65.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.18 in the past 14 days, which was higher than the 0.13 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.32, while its 200-day Moving Average is $2.77. However, in the short run, Cardiff Oncology Inc’s stock first resistance to watch stands at $3.08. Second resistance stands at $3.22. The third major resistance level sits at $3.31. If the price goes on to break the first support level at $2.86, it is likely to go to the next support level at $2.77. Now, if the price goes above the second support level, the third support stands at $2.63.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
There are 67,361K outstanding shares of the company, which has a market capitalization of 198.71 million. As of now, sales total 680 K while income totals -45,430 K. Its latest quarter income was 120 K while its last quarter net income were -11,260 K.
